Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study
Trine Trab(University of Copenhagen), Kirsten Grønbæk(University of Copenhagen), Thomas Stauffer Larsen(Odense University Hospital), Mats Jerkeman(Lund University), Tarec Christoffer El‐Galaly(Aalborg University Hospital), Iman Chanchiri(Odense University Hospital), Mikkel Runason Simonsen(Aalborg University Hospital), Ahmed Ludvigsen Al‐Mashhadi(Aarhus University Hospital), Christian Bjørn Poulsen(University of Copenhagen), Laura Mors Haunstrup(Aalborg University Hospital), Simon Husby(Copenhagen University Hospital), Mikael Frederiksen(Hospital South West Jutland), Mette Johansen(Aarhus University Hospital), Peter C. Brown(Rigshospitalet), Michael Roost Clausen(Vejle Sygehus), Jacob Haaber Christensen(Odense University Hospital), Robert Schou Pedersen
Cited by 4
Related Papers
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337